New VIVUS, Inc. CEO to Focus on Retail Push for Diet Pill
Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!
Vivus Inc's new CEO plans to keep a tight lid on costs and focus on rolling out the company's diet pill via retail pharmacies in the next two quarters, after the product's sales missed analysts' estimates for the fourth quarter in a row. In his first public comments since taking the top job at Vivus, Zook said overcoming barriers to patients' access to the diet drug, Qsymia, will be among the company's top priorities in the next few months. As part of that strategy, Vivus does not plan on launching an expensive direct-to-consumer campaign for Qsymia in the near term, said Zook, who was picked as CEO by the company's largest shareholder First Manhattan Co after a bitter proxy battle that also brought about a board shuffle last month.
Help employers find you! Check out all the jobs and post your resume.
Vivus Inc's new CEO plans to keep a tight lid on costs and focus on rolling out the company's diet pill via retail pharmacies in the next two quarters, after the product's sales missed analysts' estimates for the fourth quarter in a row. In his first public comments since taking the top job at Vivus, Zook said overcoming barriers to patients' access to the diet drug, Qsymia, will be among the company's top priorities in the next few months. As part of that strategy, Vivus does not plan on launching an expensive direct-to-consumer campaign for Qsymia in the near term, said Zook, who was picked as CEO by the company's largest shareholder First Manhattan Co after a bitter proxy battle that also brought about a board shuffle last month.
Help employers find you! Check out all the jobs and post your resume.